Cascade Investment Holds 6.2% Of Ginkgo Bioworks With Sole Voting Authority
The Gates holding company reported 3,322,584 Class A shares and certified that the position was held without a control-changing purpose.
Cascade Investment, William H. Gates III's personal holding company, reported a 6.2% stake in Ginkgo Bioworks, which provides biological research services and laboratory tools, in an amended SEC ownership disclosure Monday. Cascade holds 3,322,584 Class A shares and has sole authority to vote the entire position.
Cascade's Shares, Gates's Reporting Obligation
Gates is Cascade's sole member and joins the company as a reporting person. That relationship means he may be treated as a beneficial owner — someone credited with ownership for disclosure purposes — of the shares held by Cascade.
The two reporting entries describe the same Cascade holding. Each lists 3,322,584 shares, with sole voting authority over all of them and no shared voting authority.
The position is dated September 30. Its 6.2% calculation uses 53,943,682 Class A shares outstanding on October 30, a figure Ginkgo reported in its quarterly filing on November 9, 2026.
Cascade and Gates certified that they acquired and hold the shares without a purpose or effect of changing or influencing Ginkgo's control. The percentage describes ownership of Class A stock, and the voting authority describes who can cast the votes attached to that holding.
A Patient Stake In Biological Research
Cascade's investment approach centers on large, patient holdings. Its Ginkgo position fits that long-term approach.
Ginkgo helps customers develop medicines, agricultural products, food ingredients and industrial chemicals. Its cell engineering business charges for research programs, automated laboratory systems, data generation and support, and customers can license biological assets.
The company's biosecurity business primarily serves governments. Canopy gathers and analyzes environmental samples, while Horizon monitors biological threats worldwide.
Ginkgo's operations are anchored in Boston, with laboratory partners around the world. The company had a market capitalization of $623 million as of 5:21 p.m. ET Monday.